Profitelligence Profitelligence · Filing Ledger Open LLY research →

Form 8-K · Current Report · Filed 2025-02-12

Eli Lilly Announces New Note Issuance

On February 10, 2025, Eli Lilly and Company announced the issuance and sale of multiple series of Notes totaling $6.46 billion in net proceeds.

Filer
Eli Lilly and Company LLY · NYSE
Filed
Accession
0001193125-25-025057
CIK
0000059478
Signal
Low impactHealthcare

Details

The Notes, with various maturities and interest rates, were issued under an Indenture dated February 1, 1991. The proceeds were realized after underwriting discounts and before estimated offering expenses.

Items reported

Item 8.01

Other Events

Corporate Update
Item 9.01

Financial Statements and Exhibits

Exhibits Furnished

Market reaction

Close before filing

$865.00

Next session

+0.8%

Since filing

+32.8%

Latest close

$1,148.84

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from LLY reporting the same item, with the next session's move:

Exhibits (4)

About Eli Lilly and Company

Eli Lilly and Company is a renowned pharmaceutical corporation that engages in the discovery, development, manufacturing, and marketing of pharmaceutical products worldwide. The company's core purpose is to create high-quality medications that address significant medical needs in areas such as oncology, immunology, neuroscience, and endocrinology. Eli Lilly is particularly noted for its pioneering work in diabetes care with products like insulin and for its innovative approach to treating complex health conditions. With a history dating back to 1876, the Indianapolis-based company blends scientific innovation with a commitment to improve patient outcomes. Eli Lilly’s role in the financial markets is significant due to its contributions to healthcare advancements and its influence on global pharmaceutical trends. The company's robust pipeline and emphasis on research and development underscore its potential to impact healthcare solutions and deliver sustainable growth. Its products and services are marketed globally, underlying its importance in the biopharmaceutical industry.

Exchange NYSE Industry Drug Manufacturers - General Company website ↗

Never miss another LLY filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts